Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 21, 2015; 21(31): 9297-9316
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9297
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9297
Table 2 Controlled trials in adjuvant chemotherapy for pancreatic ductal adenocarcinoma
Study name | No. of patients enrolled | Regimen | Survival rate | P value | Ref. |
CONKO-001 | 368 | Gemcitabine | 20.7% (5 yr) | 0.01 | [145] |
Observation | 10.4% (5 yr) | ||||
ESPAC-3 | 1088 | Gemcitabine | 23.6 mo | 0.39 | [146] |
5-FU + Leucovorin | 23.0 mo | ||||
JASPAC 01 | 385 | Gemcitabine | 53% | 0.0001 | [64] |
S-1 | 70% |
- Citation: Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316
- URL: https://www.wjgnet.com/1007-9327/full/v21/i31/9297.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i31.9297